Mistletoe ( Viscum album ) extract targets Axl to suppress cell proliferation and overcome cisplatin- and erlotinib-resistance in non-small cell lung cancer cells-Reference-Cited by-同舟云学术

Mistletoe ( Viscum album ) extract targets Axl to suppress cell proliferation and overcome cisplatin- and erlotinib-resistance in non-small cell lung cancer cells

Published:2017-12 Issue: Volume:36 Page:183-193
ISSN:0944-7113
Container-title:Phytomedicine
language:en
Short-container-title:Phytomedicine

Author:

Kim Soyoung,Kim Kyung-Chan,Lee ChuHee

Funder

Yeungnam University

Publisher

Elsevier BV

Subject

Complementary and alternative medicine,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine

Reference62 articles.

1. Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line;Al-Farsi;Front. Oncol.,2014

2. Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer;Bae;Oncotarget,2015

3. First-line crizotinib shows promise in patients with NSCLC;Bagcchi;Lancet Respir. Med.,2015

4. Estrogen dependent expression of the receptor tyrosine kinase Axl in normal and malignant human breast;Berclaz;Ann. Oncol.,2001

5. Targeting inflammation in cancer-related-fatigue: a rationale for mistletoe therapy as supportive care in colorectal cancer patients;Bock;Inflamm. Allergy Drug Targets,2014

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mistletoe Extracts from Different Host Trees Disparately Inhibit Bladder Cancer Cell Growth and Proliferation;Cancers;2023-10-04

2. Wogonin inhibits hepatoma cell proliferation by targeting miR‐27b‐5p/YWHAZ axis;Journal of Biochemical and Molecular Toxicology;2023-08-25

3. Viscum album Induces Apoptosis by Regulating STAT3 Signaling Pathway in Breast Cancer Cells;International Journal of Molecular Sciences;2023-07-26

4. The Anti-Inflammatory Activity of Viscum album;Plants;2023-03-27

5. The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas;Cancers;2023-03-08